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Edi tor i a l
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
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Breathing New Life into Interstitial Lung Disease  
in Rheumatoid Arthritis
Peter K. Gregersen, M.D., and Ellen M. Gravallese, M.D.
Clinical heterogeneity is a hallmark of many auto-
immune disorders, and clinical or subclinical 
pulmonary involvement is a common extraarticu-
lar feature of the rheumatoid arthritis (RA) phe-
notype. High-resolution computed tomography 
reveals evidence of pulmonary abnormalities in 
more than half of patients with RA, and clini-
cally significant interstitial lung disease (ILD) 
will develop in approximately 10% of patients.1 
It is currently difficult to identify these patients 
and to intervene early in the clinical course of 
their lung disease.
The application of genomewide association 
studies to the search for common genetic variants 
involved in autoimmune and inflammatory dis-
eases has produced a rich harvest of hundreds of 
genetic associations. However, most of these 
associations have low effect sizes, and practical 
implications for understanding, diagnosing, and 
treating these disorders have been extremely slow 
to emerge. In the case of RA, the effect of HLA 
genes dominates over the other 100 confirmed 
genetic associations.2 Although HLA genes con-
trol some of the immunologic features of the dis-
ease, the effect of HLA on other clinical features, 
including lung disease, is modest. In fact, no clear 
subsets of disease have been identified from 
consideration of other genetic variants. The re-
port by Juge et al. now appearing in the Journal 
provides an exciting exception to this trend.3
Genetic studies involving people with idio-
pathic pulmonary fibrosis have implicated a num-
ber of common and rare genetic variants in dis-
ease pathogenesis, the strongest of which is a 
gain-of-function promoter variant in MUC5B 
(rs35705950)4; this accounts for approximately 
30 to 35% of the genetic risk of the development 
of idiopathic pulmonary fibrosis. Strikingly, in 
the current study by Juge et al. involving patients 
with RA, those who carried this variant had a 
higher risk of ILD than those who did not, with 
an odds ratio of 3.1 (95% confidence interval, 
1.8 to 5.4), even when the researchers took into 
account smoking (a known risk factor for both 
ILD and RA), age, and sex. This promoter variant 
does not confer risk of interstitial pneumonia 
among patients with systemic sclerosis.5 The 
increased risk that was associated with the vari-
ant was found across multiple ethnic groups 
(with the exception of Asians, for whom the 
sample sizes and the rarity of the risk allele 
limited statistical power), a finding that adds to 
the likelihood that this is indeed a causative 
variant. Several other common variants that have 
previously been associated with the risk of ILD 
did not show this effect in the context of RA, 
although the sample sizes in the current study 
do not provide the power to test for these more 
modest associations.
The pathogenesis of idiopathic pulmonary fi-
brosis almost certainly involves several mecha-
nisms, including abnormalities in surfactant se-
cretion leading to alveolar damage, predisposition 
to cell senescence associated with telomere short-
ening, and interference with ciliary clearance. 
Mucins are glycosylated proteins that represent 
an important component of the mucus that ad-
heres to ciliated epithelium in the lung, provid-
ing a defensive barrier, as well as a clearance 
mechanism for inhaled particles and pathogens. 
As Juge and colleagues show, the MUC5B protein 
is expressed in bronchiolar epithelium and in 
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metaplastic epithelia lining the honeycomb cysts 
typical of RA-associated ILD. Genetically driven 
overexpression of MUC5B may contribute to over-
production of MUC5B protein, with subsequent 
interference in ciliary clearance, or disrupt nor-
mal lung-repair mechanisms.6
Paradoxically, in addition to being associated 
with an elevated level of expression and risk of 
disease, the MUC5B promoter risk allele is also 
associated with an improved outcome in patients 
with idiopathic pulmonary fibrosis.7 The preva-
lence of this allele in many populations suggests 
that it may be under selection pressure, perhaps 
driven by improved resistance to infection or 
enhanced tissue repair. A late-onset illness such 
as ILD is highly unlikely to be a major selective 
disadvantage.6 In the event that an improved out-
come of lung disease in patients with RA with 
the MUC5B risk allele is observed, one might 
hypothesize that other patients with RA with 
ILD but who lack the MUC5B risk allele carry 
more rare risk alleles in other genes acting in 
different pathways.
Fujii et al. have previously reported that short-
ened telomeres are a feature of patients with 
RA,8 and there is evidence for accelerated telo-
mere shortening in patients with ILD who carry 
risk alleles in this pathway. Moreover, in a recent 
small study, persons with RA and ILD who car-
ried rare risk alleles in genes encoding proteins 
that regulate telomere length (TERT, RTEL1, and 
PARN) also exhibited telomere shortening.9 Al-
though there are many intriguing possibilities to 
explain shortened telomeres in patients with RA, 
the association of RA with ILD may be a partial 
explanation. Genes in the telomere pathway were 
not implicated in the genomewide association 
studies of RA.10 Because the genotyping chips 
used in genomewide association do not detect 
rare variants, it remains possible that rare vari-
ants in this pathway cause susceptibility to RA, 
with or without concomitant ILD. In addition, 
common variants, such as MUC5B, may yet show 
up in future genomewide association studies of 
RA using updated genotyping platforms that bet-
ter capture common variation at certain loci.
The strong association of the MUC5B promoter 
variant with ILD in patients with RA raises the 
question of whether all patients with RA should 
be evaluated for MUC5B carrier status. This will be 
most appropriate when early detection can man-
date preventive or effective therapies. On the 
other hand, once clinical disease is present, 
MUC5B genotyping might provide information on 
prognosis and, as understanding of pathogene-
sis improves, may guide management. Overall, 
the results of Juge et al. support the concept that 
genetics really can add to our understanding of 
disease heterogeneity, and the results provide 
hope that this approach will lead to further 
insights in the future.
Disclosure forms provided by the authors are available with 
the full text of this editorial at NEJM.org.
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